Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Studies from University of North Carolina describe new findings in cancer
April 10th, 2008
"Context The Women's Health Initiative ( WHI) trial of estrogen plus progestin vs placebo was stopped early, after a mean 5.6 years of follow- up, because the overall health risks of hormone therapy exceeded its benefits. To report health outcomes at 3 years ( mean 2.4 years of follow- up) after the intervention was stopped," scientists in the United States report. "Setting, and Participants The intervention phase was a double- blind, placebo- controlled, randomized trial of conjugated equine estrogens ( CEE) 0.625 mg daily plus medroxyprogesterone acetate ( MPA) 2.5 mg daily, in 16 608 women aged 50 through 79 years, recruited by 40 centers from 1993 to 1998. The...
Source: Women's Health Weekly (2008-04-10)
|
